Unknown

Dataset Information

0

Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer.


ABSTRACT: Many critical issues remain concerning how best to deploy adoptive regulatory T cell (Treg) immunotherapy to the clinic. These include a determination of their pharmacokinetic characteristics, their optimal dose, their phenotypic stability and the best therapies with which to pair Tregs. By performing a CFSE-labeled autologous Treg pulse experiment, we determined that the accessible peripheral blood Treg pool in rhesus macaques is quite large (75?±?11?×?10(6)?Tregs/kg). Pharmacokinetic analysis revealed that Tregs have two phases of elimination: an ? phase, with a T1/2 in the peripheral blood of 32.4?±?11.3?h and a ? phase with a T1/2 of 120.4?±?19.7?h. In addition to their short initial half-life, Tregs underwent rapid phenotypic shifts after infusion, with significant loss of both CD25 and FoxP3 by day +6. While tacrolimus stabilized CD25 expression, it did not improve T1/2 , nor mitigate the loss of FoxP3. In contrast, rapamycin significantly stabilized both CD25 and FoxP3, and supported an increased half-life, with an ? phase of 67.7?±?6.9?h and a ? phase of 252.1?±?54.9?h. These results suggest that rapamycin may be a necessary addition to Treg immunotherapy, and that tacrolimus may be deleterious to Treg integrity posttransfer.

SUBMITTER: Singh K 

PROVIDER: S-EPMC4236286 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer.

Singh K K   Stempora L L   Harvey R D RD   Kirk A D AD   Larsen C P CP   Blazar B R BR   Kean L S LS  

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20141030 12


Many critical issues remain concerning how best to deploy adoptive regulatory T cell (Treg) immunotherapy to the clinic. These include a determination of their pharmacokinetic characteristics, their optimal dose, their phenotypic stability and the best therapies with which to pair Tregs. By performing a CFSE-labeled autologous Treg pulse experiment, we determined that the accessible peripheral blood Treg pool in rhesus macaques is quite large (75 ± 11 × 10(6) Tregs/kg). Pharmacokinetic analysis  ...[more]

Similar Datasets

| S-EPMC304106 | biostudies-other
2018-07-01 | GSE56113 | GEO
| S-EPMC7610430 | biostudies-literature
| S-EPMC4893316 | biostudies-literature
| S-EPMC4176515 | biostudies-literature
| S-EPMC3196783 | biostudies-literature
| S-EPMC3828296 | biostudies-literature
| S-EPMC3182363 | biostudies-literature
| S-EPMC5939619 | biostudies-literature
| S-EPMC9896856 | biostudies-literature